BACKGROUND INFORMATION ON THE PROCEDURE 
1 
Submission of the dossier 
The  applicant  Astellas  Pharma  GmbH  submitted  on  18  January  2006  an  application  for  Marketing 
Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Advagraf,  through  the  centralised 
procedure under Article 3 (2) (b) of Regulation (EC) No 726/2004. The eligibility to the centralised 
procedure was agreed upon by the EMEA/CHMP on 14 December 2005. 
The legal basis for this application refers to:  
Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application 
The application submitted is a complete dossier: 
composed of administrative information, complete quality data, non-clinical and clinical data based on 
applicants’ own tests and studies and/or bibliographic literature substituting/supporting certain test or 
study. 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: 
Rapporteur: Dr David Lyons 
Co-Rapporteur: Romaldas Maciulaitis 
2 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The application was received by the EMEA on 18 January 2006.  
The procedure started on 1 March 2006. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on 
22  May  2006.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP 
members on 22 May 2006. 
During  the  meeting  from  26-28  June  2006,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on  29 June 2006. 
The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on 
28 September 2006. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on  10 November 2006. 
During the CHMP meeting on 11-14 December 2006, the CHMP agreed on a list of outstanding 
issues to be addressed in writing by the applicant. 
The  applicant  submitted  written  explanations  to  the  CHMP  List  of  Outstanding  Issues  on 
26 January 2007. 
During  the  meeting  from  19-22  February  2006  the  CHMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation to Advagraf on 22 February 2006. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decision on 23 April 2007. 
1/1 
©EMEA 2007 
 
 
 
 
 
 
 
 
 
 
 
